These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 34508834

  • 1. Pathophysiology and Management of Hyperoxaluria and Oxalate Nephropathy: A Review.
    Demoulin N, Aydin S, Gillion V, Morelle J, Jadoul M.
    Am J Kidney Dis; 2022 May; 79(5):717-727. PubMed ID: 34508834
    [Abstract] [Full Text] [Related]

  • 2. A hidden cause of oxalate nephropathy: a case report.
    Mahmoud T, Ghandour EC, Jaar BG.
    J Med Case Rep; 2021 Mar 08; 15(1):106. PubMed ID: 33678172
    [Abstract] [Full Text] [Related]

  • 3. Update on oxalate crystal disease.
    Lorenz EC, Michet CJ, Milliner DS, Lieske JC.
    Curr Rheumatol Rep; 2013 Jul 08; 15(7):340. PubMed ID: 23666469
    [Abstract] [Full Text] [Related]

  • 4. [Bilateral nephrocalcinosis: primary hyperoxaluria involved].
    Deprez T, Sempels M.
    Rev Med Liege; 2022 Jul 08; 77(7-8):416-420. PubMed ID: 35924494
    [Abstract] [Full Text] [Related]

  • 5. Purslane-induced oxalate nephropathy: case report and literature review.
    Wang X, Zhang X, Wang L, Zhang R, Zhang Y, Cao L.
    BMC Nephrol; 2023 Jul 13; 24(1):207. PubMed ID: 37443012
    [Abstract] [Full Text] [Related]

  • 6. Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.
    Michael M, Groothoff JW, Shasha-Lavsky H, Lieske JC, Frishberg Y, Simkova E, Sellier-Leclerc AL, Devresse A, Guebre-Egziabher F, Bakkaloglu SA, Mourani C, Saqan R, Singer R, Willey R, Habtemariam B, Gansner JM, Bhan I, McGregor T, Magen D.
    Am J Kidney Dis; 2023 Feb 13; 81(2):145-155.e1. PubMed ID: 35843439
    [Abstract] [Full Text] [Related]

  • 7. Recurrence of crystalline nephropathy after kidney transplantation in APRT deficiency and primary hyperoxaluria.
    Bollée G, Cochat P, Daudon M.
    Can J Kidney Health Dis; 2015 Feb 13; 2():31. PubMed ID: 26380104
    [Abstract] [Full Text] [Related]

  • 8. The management of patients with enteric hyperoxaluria.
    Asplin JR.
    Urolithiasis; 2016 Feb 13; 44(1):33-43. PubMed ID: 26645872
    [Abstract] [Full Text] [Related]

  • 9. Pathophysiology and management of enteric hyperoxaluria.
    Desenclos J, Forté V, Clément C, Daudon M, Letavernier E.
    Clin Res Hepatol Gastroenterol; 2024 May 13; 48(5):102322. PubMed ID: 38503362
    [Abstract] [Full Text] [Related]

  • 10. End Point Considerations for Clinical Trials in Enteric Hyperoxaluria.
    Langman CB, Assimos D, Blank M, Calle J, Grauer A, Kausz A, Milliner D, Nazzal L, Smith K, Tasian G, Thompson A, Wood KD, Worcester E, Yang S, Malley MA, Knauf F, Lieske JC, Rare Kidney Stone Consortium (RKSC) Kidney Health Initiative (KHI) Oxalosis and Hyperoxaluria Foundation Enteric Hyperoxaluria Workgroup (OHF EH Workgroup).
    Clin J Am Soc Nephrol; 2023 Dec 01; 18(12):1637-1644. PubMed ID: 37342976
    [Abstract] [Full Text] [Related]

  • 11. Oxalate nephropathy in an elderly patient with newly diagnosed celiac disease - a case report.
    Zijlstra HW, Stegeman CA.
    BMC Nephrol; 2023 Jun 27; 24(1):189. PubMed ID: 37370009
    [Abstract] [Full Text] [Related]

  • 12. [Oxalate: a poorly soluble organic waste with consequences].
    Lu Y, Bonny O.
    Praxis (Bern 1994); 2015 Mar 25; 104(7):353-9. PubMed ID: 25804778
    [Abstract] [Full Text] [Related]

  • 13. Acute oxalate nephropathy due to pancreatic atrophy in newly diagnosed pancreatic carcinoma.
    Moinuddin I, Bala A, Ali B, Khan H, Bracamonte E, Sussman A.
    Hum Pathol; 2016 Feb 25; 48():163-6. PubMed ID: 26614399
    [Abstract] [Full Text] [Related]

  • 14. Primary hyperoxaluria: clinical course, diagnosis, and treatment after kidney failure.
    Raju DL, Cantarovich M, Brisson ML, Tchervenkov J, Lipman ML.
    Am J Kidney Dis; 2008 Jan 25; 51(1):e1-5. PubMed ID: 18155525
    [Abstract] [Full Text] [Related]

  • 15. Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial.
    Frishberg Y, Deschênes G, Groothoff JW, Hulton SA, Magen D, Harambat J, Van't Hoff WG, Lorch U, Milliner DS, Lieske JC, Haslett P, Garg PP, Vaishnaw AK, Talamudupula S, Lu J, Habtemariam BA, Erbe DV, McGregor TL, Cochat P, study collaborators.
    Clin J Am Soc Nephrol; 2021 Jul 25; 16(7):1025-1036. PubMed ID: 33985991
    [Abstract] [Full Text] [Related]

  • 16. Oxalate nephropathy in systemic sclerosis: Case series and review of the literature.
    Ligon CB, Hummers LK, McMahan ZH.
    Semin Arthritis Rheum; 2015 Dec 25; 45(3):315-20. PubMed ID: 26239907
    [Abstract] [Full Text] [Related]

  • 17. An update on primary hyperoxaluria.
    Hoppe B.
    Nat Rev Nephrol; 2012 Jun 12; 8(8):467-75. PubMed ID: 22688746
    [Abstract] [Full Text] [Related]

  • 18. [Hyperoxaluria and renal calculi].
    Buño Soto A, Torres Jiménez R, García Puig J, Mateos Antón F.
    Arch Esp Urol; 1996 Sep 12; 49(7):707-26. PubMed ID: 9020008
    [Abstract] [Full Text] [Related]

  • 19. Initial manifestation of primary hyperoxaluria type I in adults-- recognition, diagnosis, and management.
    Kuiper JJ.
    West J Med; 1996 Jan 12; 164(1):42-53. PubMed ID: 8779202
    [Abstract] [Full Text] [Related]

  • 20. Secondary oxalate nephropathy and kidney transplantation.
    Aziz F, Jorgenson M, Garg N.
    Curr Opin Organ Transplant; 2023 Feb 01; 28(1):15-21. PubMed ID: 36342385
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.